NCT07442292Not yet recruiting
PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor
PD-L1 Targeting Peptide Probe 68Ga-cPP-BCH for PET Imaging of Solid Tumor
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 24 Feb 2026
- Start date
- 1 Feb 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Diseases
- Melanoma, Lung cancer
- NCT number
- NCT07442292
What you commit to
- Study type: Observational
- Planned participants: 40
- From 1 Feb 2026 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Suffering from claustrophobia or other mental disorders;
Other
- The function of liver and kidney was seriously abnormal;
- Preparation for pregnant, pregnant and lactating women;
- Inability to lie flat for half an hour;
- Other researchers considered it unsuitable to participate in the trial.
Who the study is looking for
- Aged 18-75, male and female, with ECOG score of 0 or 1;
- Subjects with lung cancer, melanoma, or other solid tumors scheduled for immunotherapy or combined immunotherapy;
- underwent PD-L1 IHC examination before therapy;
- The expected survival was more than 26 weeks;
- Blood routine test, liver and kidney function meet the following standards: blood routine: WBC \>= 4.0 x 10\^9/L or neutrophil \>= 1.5 x 10\^9/:, PLT \>= 100 x 10\^9 / L, Hb \>= 90g / L; Pt or APTT \<= 1.5 upper limit of normal value; liver and kidney function: total bilirubin \<= 1.5 x ULT (upper limit of normal value), ALT / AST \<= 2.5 upper limit of normal value or \<= 5 x ULT (subject with liver metastasis), ALP \<= 2.5 upper limit of normal value (if bone metastasis or liver metastasis exists, ALP \<= 4.5 upper limit of normal value); BUN \<= 1.5 x ULT, SCR \<= 1.5 x ULT;
- According to RECIST1.1, there was at least one measurable target lesion;
- Understand and sign informed consent voluntarily with good compliance.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.